Aramis Biosciences

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company dedicated to developing disease-modifying therapies for ocular surface diseases. Founded in 2018, the company builds on over a decade of research conducted at Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, where it was discovered that certain pro-inflammatory T helper cell subsets play a central role in the immunopathogenesis of dry eye disease. Since then, Aramis Biosciences has assembled a team of accomplished pharmaceutical executives and world-renowned experts in ophthalmology and immunology, all committed to the mission of revolutionizing the standard of care for ocular surface diseases. Aramis Biosciences is further supported by its strategic partners, institutional investors, and academic collaborators.